Trial Profile
A Trial to Test for Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9068 and Compared With NN1250 and NN2211 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Feb 2017
Price :
$35
*
At a glance
- Drugs Insulin degludec/liraglutide (Primary) ; Insulin degludec; Liraglutide
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 19 Sep 2014 Results of a pooled pharmacokinetic analysis of trials NCT01336023 and NCT00983021 were presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 26 Sep 2009 New trial record